Sodium glucose co-transporter 2 (SGLT2) inhibitors in heart failure with preserved ejection fraction: A systematic review and meta-analysis

Tsampasian, Vasiliki, Elghazaly, Hussein, Chattopadhyay, Rahul Kumar, Ali, Omar, Corballis, Natasha, Chousou, Panagiota Anna, Clark, Allan, Garg, Pankaj and Vassiliou, Vassilios (2022) Sodium glucose co-transporter 2 (SGLT2) inhibitors in heart failure with preserved ejection fraction: A systematic review and meta-analysis. European Journal of Preventive Cardiology, 29 (6). e227–e229. ISSN 2047-4873

[img] PDF (F1. CV death or HHF) - Accepted Version
Restricted to Repository staff only until 1 December 2022.

Request a copy
[img] PDF (Accepted_Manuscript) - Accepted Version
Restricted to Repository staff only until 1 December 2022.

Request a copy
[img] PDF (SupplMaterial_Updated) - Accepted Version
Restricted to Repository staff only until 1 December 2022.

Request a copy
[img] Microsoft Word (OpenXML) (Table_updated) - Accepted Version
Restricted to Repository staff only until 1 December 2022.

Request a copy

Abstract

Whilst heart failure with preserved ejection fraction (HFpEF) is increasingly studied, the search for a single pharmacotherapeutic agent that will improve hard endpoints like hospitalization and mortality still continues.1 Given the various subphenotypes of HFpEF,2 this makes it difficult for a single agent to be universally beneficial. The recent publication of EMPEROR-PRESEVED3 was an instrumental time for an updated meta-analysis focused on sodium glucose co-transporter 2 inhibitors (SGLT2i) use in HFpEF.

Item Type: Article
Faculty \ School: Faculty of Medicine and Health Sciences > Norwich Medical School
Depositing User: LivePure Connector
Date Deposited: 28 Oct 2021 00:49
Last Modified: 13 May 2022 11:30
URI: https://ueaeprints.uea.ac.uk/id/eprint/81902
DOI: 10.1093/eurjpc/zwab189

Actions (login required)

View Item View Item